Expression of LOX-1 in human mesangial cells is increased by Ox-LDL and IL-1β treatment
- Authors:
- Published online on: August 16, 2017 https://doi.org/10.3892/etm.2017.4950
- Pages: 3632-3636
-
Copyright: © Deng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
The present study aimed to determine whether the expression of lectin‑like oxidized LDL receptor 1 (LOX‑1) could be induced by oxidized low‑density lipoprotein (Ox‑LDL) and interleukin 1β (IL‑1β) in human mesangial cells (HMCs). Oil Red O staining was used to observe the uptake of Ox‑LDL by HMCs stimulated with IL‑1β, and reverse transcription‑quantitative polymerase chain reaction analysis and western blotting were used to examine the expression of LOX‑1 in HMC following Ox‑LDL and IL‑1β treatment. Uptake of Ox‑LDL by HMCs was upregulated upon stimulation with IL‑1β. Furthermore, Ox‑LDL (10‑40 µg/ml) treatment induced LOX‑1 mRNA and protein expression in a dose‑dependent manner. In addition, when HMCs were treated with IL‑1β and Ox‑LDL, the expression of LOX‑1 was enhanced further. These results indicated that inhibiting LOX‑1 expression or inhibiting the Ox‑LDL/LOX‑1 signaling axis may be a potential novel method for treating renal disease.
